Tuesday 2nd December – Day 2 Main Conference - GMT (Greenwich Mean Time, GMTZ)
While the 20th century was the century of the discovery of the DNA structure (Watson and Crick, Nobel Prize 1962) and of the birth of the modern human genetics field, the 21st century is- and should properly be- the century of applying this knowledge on genes and genetics in treating fastidious human diseases. New fields such as gene and cell therapies are thus slowly emerging out of the womb of human genetics— from CRISPR and CRISPR therapeutics to various gene therapies. In this Keynote talk, we will describe recent advances in genetic engineering of disease models and of new therapies, as well as the challenges to be overcome in the future. We will outline the future milestones for the gene therapy field.
- Regine Heilbronn - Co-Founder and CEO, EpiBlok Therapeutics
- Round Table 1: AI Revolution in CGT Manufacturing – Beyond the Hype: Where is it Having an Impact?
Leader: Guido Moll, Assistant Coordinator EU-H2020 ATMP & GMP Projects, Charité, Universitätsmedizin Berlin
- Round Table 2: From Rare Diseases to Mainstream Markets: Unlocking CGT's Potential for Major Disease Indications
Leader: Hiroyuki Usuda, Scouting & Transaction Lead, Business Development, Astellas Pharma Europe Ltd
